M
MXCT
Maxcyte
1.190
-0.050-4.03%Closed16:10 09/24 EDT
OPEN/PREV CLOSE1.020/1.020
TODAY RANGE0.9900-1.030
VOL240.01K
MARKET CAP104.24M
52 WEEK RANGE0.6434-1.865
AVG VOL (3M)662.35K
% TURNOVER0.23%
TURNOVER--
P/E (TTM)-3.0249
% RANGE3.92%
EPS(TTM)-0.3339
P/E(FORWARD)-3.6331
P/B0.6752
BVPS1.496
DIVIDEND--
P/S3.265
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP97.23M
SHARES OUTSTANDING103.21M
NEXT EARNINGS11/16-11/29
FREE FLOAT96.27M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
NASDAQ·08/19 12:26
MaxCyte Launches New Off-Target Assays For Base Editing Therapies
Benzinga·08/19 12:07
MaxCyte Launches CHANGE-seq-BE And ONE-seq-BE Off-Target Nomination Assays
Simply Wall St·08/14 22:30
MaxCyte (MXCT) Stock Price Reflects Faith In Royalties Over Core Weakness
TipRanks·08/13 15:35
Stifel Nicolaus Keeps Their Buy Rating on MaxCyte (MXCT)
TipRanks·08/13 15:00
Analysts’ Top Healthcare Picks: MaxCyte (MXCT), Definium Therapeutics (DFTX)
NASDAQ·08/13 01:04
MaxCyte Q2 Earnings Call Highlights
TipRanks·08/13 00:04
MaxCyte (MXCT) Earnings Call Signals Stabilizing Turnaround
NASDAQ·08/12 22:15
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates
Benzinga·08/12 21:06
12 Health Care Stocks Moving In Wednesday's After-Market Session
TipRanks·08/12 20:57
MaxCyte Reports Q2 Results, Highlights Genentech Partnership
NASDAQ·08/11 12:20
Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates
NASDAQ·08/05 12:15
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
Same Industry
Name/Symbol
Change%
Price